TABLE 2.
Inhibitor status after FVIII reexposure for bleeds or surgery
| Patient no. | Post‐ITI tolerance status | Emicizumab Regimen |
Bleeding event or surgery (no. of bleeds if > 1) |
FVIII ED at inhibitor testing, d | Inhibitor titer after FVIII reexposure (CBU/mL) a | Anti‐FVIII antibody detection after FVIII reexposure | Interval from last ED to repeat antibody testing, mo | |
|---|---|---|---|---|---|---|---|---|
| 1 | Success | 1.5 mg/kg Q1 wk |
Hemarthroses—Ankle (4), Knee (2), and Elbow Musculoskeletal injuries—back, hip CVL removal |
17 | <0.5 | IgG1 − | IgG4 − | 3 |
| 5 | Partial | 1.5 mg/kg Q1 wk | Epidural hematoma, spinal cord decompression, and hemilaminectomy | 30 | <0.5 | IgG1 − | IgG4 − | 6 |
| 6 | Success | 3 mg/kg Q2 wk |
Hip bleed Triceps muscle hematoma |
3 | <0.5 | IgG1 − | IgG4 + | 4 |
| 9 | Success | 3 mg/kg Q2 wk | CVL‐associated bleed | 1 | <0.5 | IgG1 − | IgG4 − | 10 |
| 10 | Success | 3 mg/kg Q2 wk |
Knee hemarthroses (3) CVL removal |
6 | <0.5 | IgG1 − | IgG4 − | 8 |
| 11 | Success | 1.5 mg/kg Q1 wk | Elbow hemarthrosis | 3 | <0.5 | IgG1 − | IgG4 + | 2 |
Abbreviations: CBU/mL, chromogenic Bethesda units per milliliter; CVL, central venous line; ED, exposure days; FVIII, factor VIII; ITI, immune tolerance induction.
a
Negative chromogenic inhibitor titer <0.5 CBU/mL.